ストックスクリーナーアプリを入手
25.68
5.62%
-1.53
前日終値:
$27.21
開ける：
$27.06
24時間の取引高:
1.38M
Relative Volume:
0.79
時価総額：
$4.08B
収益：
$1.27M
当期純損益:
$-508.02M
株価収益率:
-8.9145
EPS:
-2.8807
ネットキャッシュフロー:
$-419.23M
1週間 パフォーマンス:
-0.58%
1か月 パフォーマンス:
+24.60%
6か月 パフォーマンス:
+50.35%
1年 パフォーマンス:
+67.30%
1日の値動き範囲:
$25.25
$27.11
1週間の範囲:
$25.05
$27.30
52週間の値動き範囲:
$12.58
$27.30
Denali Therapeutics Inc Stock (DNLI) Company Profile
名前
Denali Therapeutics Inc
セクター
電話
(650) 866-8547
住所
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
25.68 | 4.08B | 1.27M | -508.02M | -419.23M | -2.8807 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-02-24 | 開始されました | Wolfe Research | Peer Perform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-04-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2025-01-07 | 開始されました | Robert W. Baird | Outperform |
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-12-16 | アップグレード | Stifel | Hold → Buy |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 開始されました | B. Riley Securities | Buy |
| 2023-01-30 | 開始されました | SVB Securities | Outperform |
| 2022-12-05 | 開始されました | Cowen | Outperform |
| 2022-11-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-02 | 開始されました | BofA Securities | Buy |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-09-21 | 開始されました | Oppenheimer | Outperform |
| 2021-09-01 | 開始されました | SMBC Nikko | Outperform |
| 2021-05-18 | 開始されました | UBS | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-02-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-02-24 | 開始されました | Jefferies | Buy |
| 2020-02-19 | 開始されました | Stifel | Hold |
| 2020-01-27 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-26 | 開始されました | Wedbush | Neutral |
| 2019-09-13 | 開始されました | Nomura | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 開始されました | Janney | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | 開始されました | Goldman | Neutral |
| 2018-01-02 | 開始されました | JP Morgan | Overweight |
| 2018-01-02 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Denali Therapeutics Inc (DNLI) 最新ニュース
Denali Therapeutics (DNLI) Investor Day 2025 Summary - Quartr
T. Rowe Price’s 10% Stake and Avlayah Approval Could Be A Game Changer For Denali Therapeutics (DNLI) - Sahm
Denali CEO to open AAIC 2026 with brain-delivery plan for Alzheimer’s - Stock Titan
Denali Therapeutics stock hits 52-week high at $26.95 - Investing.com
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Denali Therapeutics stock hits 52-week high at $26.95 By Investing.com - Investing.com Canada
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth? - TradingView
T. Rowe Price holds 10.2% of Denali Therapeutics (DNLI) in 13G/A - Stock Titan
Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart.com
Trading Systems Reacting to (DNLI) Volatility - Stock Traders Daily
DNLIDenali Therapeutics Inc Volatility & Greeks - Finviz
Denali Therapeutics (DNLI) Looks Fully Valued Following Its 32% 30 Day Rally - Sahm
Denali Therapeutics stock stays focused on pipeline progress. - ad-hoc-news.de
Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK - Barchart.com
Denali to sell priority review voucher for $195M cash boost - MSN
Enterprise value to EBIT forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Price to sales forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc (DNLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh - TradingView
Price to earnings forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Price to book forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc. Actuals & Estimates (NASDAQ:DNLI) - TradingView
Enterprise value to EBITDA forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
4DN Forecast — Price Target — Prediction for 2027 - TradingView
Denali Therapeutics Inc. Actuals & Estimates (DUS:4DN) - TradingView
How Denali Therapeutics Inc. (DNLI) Affects Rotational Strategy Timing - Stock Traders Daily
Denali Therapeutics options trading jumps to 2,291 contracts By Investing.com - Investing.com India
Denali Therapeutics options trading jumps to 2,291 contracts - Investing.com
Denali Therapeutics stock hits 52-week high at 25.74 USD By Investing.com - Investing.com Nigeria
Denali Therapeutics stock hits 52-week high at 25.74 USD - Investing.com
DNLI Forecast — Price Target — Prediction for 2027 - TradingView
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate - Moomoo
Denali Therapeutics (DNLI) Q1 2026 earnings summary - Quartr
Denali Therapeutics Sells Rare Pediatric Disease Priority Review Voucher for $195 Million - Global Legal Chronicle
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II - Yahoo Finance
Denali Therapeutics (DNLI) Looks Fully Valued After $195 Million Voucher Sale - Sahm
Why Denali Therapeutics (DNLI) Is Up 8.2% After Selling Its Priority Review Voucher For $195 Million - simplywall.st
Stifel reiterates Buy rating on Denali Therapeutics stock at $41 By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Denali stock, cites launch progress By Investing.com - Investing.com India
Stifel reiterates Buy rating on Denali Therapeutics stock at $41 - Investing.com
Stifel reiterates Buy rating on Denali stock, cites launch progress - Investing.com
Denali to sell priority review voucher for $195M - MSN
Denali Therapeutics StockAnalyst focus and sector check after a quiet news week - AD HOC NEWS
Denali to Sell Priority Review Voucher for $195M Cash Boost - TradingView
Denali Therapeutics Inc (DNLI) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):